AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including CoVID-19

New York, NY – April 21, – AIkido Pharma Inc. (NASDAQ: AIKI) (“AIkido” or the “Company”) today announced that on April 13, 2020, the Company executed a Master License Agreement (the “License Agreement”) with the University of Maryland, Baltimore (“UMB”). The License Agreement covers specific antiviral compounds discovered by UMB. The compounds seek to inhibit replication […]